logo

For the Inventor, By the Inventor

Taejon, South Korea

Young-Soo Hong

This inventor holds 4 USPTO granted patents. Top assignee: Korea Research Institute of Bioscience and Biotechnology. Active years: 2002-2013.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Young-Soo Hong. Retrieved from https://idiyas.com/inventor/young-soo-hong-qx2ttuxb

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 4

% Patents Active = 25.0

Average Co-Inventor Count = 5.5

ph-index = 2

Forward Citations = 33(Granted Patents)


Location History:

  • Taejon-si, KR (2002 - 2005)
  • Taejeon-si, KR (2013)

Company Filing History:

goldMedal4 out of 335 
 
Korea Research Institute of Bioscience and Biotechnology
 patents

Years Active: 2002-2013

Loading Chart...
4 patents (USPTO):Explore Patents
1. 8394799 - Compounds that inhibit HIF-1 activity, the method for preparation thereof and the pharmaceutical composition containing them as an effective component (2013-03-12),
2. 6894073 - Use of diterpene compound as a therapeutic agent of inflammation, immune disease or cancer (2005-05-17),
3. 6770671 - 7,8-dihydro-xanthenone-8-carboxylic acid derivative and novel microbe producing the same (2004-08-03),
4. 6451846 - Isocoumarin derivatives inhibiting angiogenesis (2002-09-17),

Title: Young-Soo Hong: Innovator in Cancer Therapeutics

Introduction

Young-Soo Hong is a prominent inventor based in Taejon-si, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of compounds that target cancer and other diseases. With a total of 4 patents to his name, his work is paving the way for innovative therapeutic solutions.

Latest Patents

Among his latest patents, Young-Soo Hong has developed compounds that inhibit HIF-1 activity. This invention includes a method for the preparation of these compounds and a pharmaceutical composition that contains them as an effective component. The HIF-1 inhibitor demonstrates anticancer activity by inhibiting HIF-1, a transcription factor crucial for cancer growth and metastasis, without causing general cytotoxicity. This makes the HIF-1 inhibitor a potential therapeutic option for various cancers, including liver, stomach, and breast cancer. Additionally, the compound is beneficial in treating diabetic retinopathy and arthritis, conditions exacerbated by HIF-1-mediated VEGF expression.

Another notable patent involves the use of diterpene compounds as therapeutic agents for inflammation, immune diseases, or cancer. This invention highlights the novel applications of diterpene compounds, such as kamebanin, kamebacetal A, kamebakaurin, and exisanin A. These compounds are effective in treating inflammation and immune diseases by inhibiting the production of nitric oxide, prostaglandin, and TNF through the suppression of NF-κB activity.

Career Highlights

Young-Soo Hong is affiliated with the Korea Research Institute of Bioscience and Biotechnology, where he conducts his research and development activities. His work is characterized by a strong focus on innovative solutions for pressing health issues, particularly in oncology and inflammatory diseases.

Collaborations

He collaborates with notable colleagues, including Jeong-Hyung Lee and Jung Joon Lee, to advance his research and enhance the impact of his inventions.

Conclusion

Young-Soo Hong's contributions to biotechnology and cancer therapeutics are noteworthy. His innovative patents reflect a commitment to addressing critical health challenges through scientific research and development. His work continues to inspire advancements in the field of medicine.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…